<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01821456</url>
  </required_header>
  <id_info>
    <org_study_id>!SZINF2</org_study_id>
    <secondary_id>!!SZINF2</secondary_id>
    <nct_id>NCT01821456</nct_id>
  </id_info>
  <brief_title>Cologne Cohort of Neutropenic Patients (CoCoNut)</brief_title>
  <acronym>CoCoNut</acronym>
  <official_title>The Cologne Cohort of Neutropenic Patients (CoCoNut) - a Non-interventional Cohort Study Assessing Risk Factors, Interventions, and Outcome of Immunosuppressed Patients With or Without Opportunistic Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital of Cologne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Cologne Cohort of Neutropenic Patients (CoCoNut) is a non-interventional cohort study
      assessing risk factors, interventions, and outcome of immunosuppressed patients with or
      without opportunistic infections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective cohort was established with the aim of a comprehensive data collection of
      all patients developing neutropenia after receiving chemotherapy for any kind of malignant
      disease, treated in the University Hospital of Cologne.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 1995</start_date>
  <completion_date type="Anticipated">December 2050</completion_date>
  <primary_completion_date type="Anticipated">December 2050</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term survival of hematology and oncology patients following neutropenia</measure>
    <time_frame>2 years following last follow-up</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100000</enrollment>
  <condition>Hematological Malignancies</condition>
  <condition>Cancer</condition>
  <condition>Chemotherapy</condition>
  <condition>Neutropenia</condition>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>Antiinfectives</arm_group_label>
    <description>To analyze the efficacy of antiinfectives at high risk patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiinfectives</intervention_name>
    <description>To analyze to efficacy of (novel) drug therapies</description>
    <arm_group_label>Antiinfectives</arm_group_label>
    <other_name>Antifungals, Antibacterials, Antivirals</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients developing neutropenia after receiving chemotherapy for any kind of malignant
        disease, treated in the University Hospital of Cologne
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  immunosuppressed patients

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital of Cologne</name>
      <address>
        <city>Cologne</city>
        <state>North Rhine-Westphalia</state>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Janne Vehreschild, Dr. med.</last_name>
      <phone>+0049 (0)221 478-6494</phone>
      <phone_ext>-6494</phone_ext>
      <email>janne.vehreschild@ctuc.de</email>
    </contact>
    <contact_backup>
      <last_name>Oliver Andreas Cornely, Prof. Dr. med.</last_name>
      <phone>0049 (0)221 478-6494</phone>
      <phone_ext>-6494</phone_ext>
      <email>oliver.cornely@ctuc.de</email>
    </contact_backup>
    <investigator>
      <last_name>Jörg J. Vehreschild, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://innere1.uk-koeln.de/klinische-schwerpunkte/infektiologie</url>
  </link>
  <results_reference>
    <citation>Vehreschild JJ, Rüping MJ, Wisplinghoff H, Farowski F, Steinbach A, Sims R, Stollorz A, Kreuzer KA, Hallek M, Bangard C, Cornely OA. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother. 2010 Jul;65(7):1466-71. doi: 10.1093/jac/dkq121. Epub 2010 Apr 21.</citation>
    <PMID>20410061</PMID>
  </results_reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2013</study_first_submitted>
  <study_first_submitted_qc>March 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2013</study_first_posted>
  <last_update_submitted>March 26, 2013</last_update_submitted>
  <last_update_submitted_qc>March 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hematological malignancies</keyword>
  <keyword>cancer</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>anti-infectives</keyword>
  <keyword>treatment</keyword>
  <keyword>outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

